Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis
Overweight and obesity increase the risk for liver cancer in patients with liver cirrhosis and long-term oral supplementation with branched-chain amino acid granules inhibits liver carcinogenesis in heavier patients with liver cirrhosis
复制标题
DOI：
10.1016/j.hepres.2006.04.007
复制
发表时间：
2006-07-01
影响因子：
4.2
通讯作者：
Ohashi, Yasuo
中科院分区：
文献类型：
--
作者：
Muto, Yasutoshi;Sato, Shunichi;Ohashi, Yasuo
我们进行了一项多中心、随机、对照试验，研究长期口服补充支链氨基酸（BCAA）对622例失代偿期肝硬化患者无事件生存期的影响。在本研究中，我们特别以肝癌的发展为终点进行分析。受试者接受12克/天的BCAA治疗或包含匹配的每日能量和蛋白质摄入量的饮食治疗。采用Cox回归分析估计不同背景因素按治疗组分层的风险比。89例患者发现肝癌。男性、合并糖尿病患者、甲胎蛋白（AFP）水平≥20 ng/mL、体重指数（BMI）较高、血清白蛋白水平较低的患者发生肝癌的风险明显较高。当比较BCAA组和饮食组与治疗组相互作用的因素时，BMI为25或更高，AFP水平为20 ng/mL或更高的BCAA组患肝癌的风险显着降低。口服补充BCAA治疗可能降低具有这些特定因素的肝硬化患者患肝癌的风险。2006爱思唯尔爱尔兰有限公司版权所有。
We conducted a multicenter, randomized, controlled trial to investigate the effect of long-term oral supplementation with branched-chain amino acids (BCAA) on the event-free survival in 622 patients with decompensated cirrhosis. In the present study, the development of liver cancer was analyzed as an endpoint in particular. Subjects received either treatment with BCAA at 12 g/day or dietary therapy containing the matched daily energy and protein intake. A Cox regression analysis was carried out to estimate the hazard ratios for different background factors stratified by treatment group. Liver cancer was noted in 89 patients. The risk for liver cancer was significantly higher for males, patients with concurrent diabetes mellims, patients with an alpha-fetoprotein (AFP) level of 20 ng/mL or higher, patients with higher body mass index (BMI), and patients with lower serum albumin levels. When the BCAA group and the diet group were compared for factors that interacted with the treatment arms, the risk for liver cancer was significantly reduced in the BCAA group with a BMI of 25 or higher and with an AFP level of 20 ng/mL or higher. Oral supplemental treatment with BCAA may reduce the risk of liver cancer in cirrhotic patients with these specific factors. (c) 2006 Elsevier Ireland Ltd. All rights reserved.